Tempest Therapeutics Stock In The News

TPST Stock  USD 8.08  0.32  4.12%   
Our overall analysis of Tempest Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Tempest Therapeutics. The specific impact of Tempest Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Tempest Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Tempest Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Tempest Therapeutics Backtesting and Tempest Therapeutics Hype Analysis.
For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

Tempest Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
https://www.globenewswire.com/news-release/2025/06/30/3107414/0/en/Tempest-Receives-Clearance-to-Proceed-with-Pivotal-Trial-of-Amezalpat-Combination-Therapy-for-First-Line-HCC-in-China.html
 Neutral
nasdaq News
Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor
https://www.nasdaq.com/articles/tempest-therapeutics-announces-46-mln-registered-direct-offering-institutional-investor
 Neutral
seekingalpha News
Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%
https://seekingalpha.com/news/4457225-tempest-announces-46-million-registered-direct-offering-of-common-stock-shares-decline-over-13?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Neutral
Macroaxis News: globenewswire.com
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
https://www.globenewswire.com/news-release/2025/06/11/3097512/0/en/Tempest-Announces-4-6-Million-Registered-Direct-Offering-of-Common-Stock.html
 Neutral
nasdaq News
Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat
https://www.nasdaq.com/articles/tempest-therapeutics-european-medicines-agency-grants-orphan-drug-designation-amezalpat
 Neutral
Macroaxis News: globenewswire.com
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
https://www.globenewswire.com/news-release/2025/05/13/3080685/0/en/Tempest-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
 Neutral
Macroaxis News: globenewswire.com
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
https://www.globenewswire.com/news-release/2025/04/28/3069640/0/en/Tempest-Presents-New-Amezalpat-MOA-Data-Reinforcing-Its-Potential-as-Novel-Cancer-Treatment-at-the-2025-AACR-Annual-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
https://www.globenewswire.com/news-release/2025/04/21/3064595/0/en/Tempest-Receives-Orphan-Drug-Designation-from-the-FDA-for-TPST-1495-to-Treat-Patients-with-FAP.html
 Neutral
Macroaxis News: globenewswire.com
Tempest Announces Plan to Explore Strate...
https://www.globenewswire.com/news-release/2025/04/09/3058883/0/en/Tempest-Announces-Plan-to-Explore-Strategic-Alternatives-to-Advance-Promising-Pipeline-of-Clinical-Oncology-Assets-and-Maximize-Stockholder-Value.html
 Bullish
news
Monday's session: gap up and gap down stocks
https://www.chartmill.com/news/DGLY/Chartmill-27347-Mondays-session-gap-up-and-gap-down-stocks
 Neutral

Tempest Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Tempest and other traded companies coverage with news coverage. We help investors stay connected with Tempest headlines for the 29th of July to make an informed investment decision based on correlating the impacts of news items on Tempest Stock performance. Please note that trading solely based on the Tempest Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Tempest Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Tempest Therapeutics investors visualize upcoming and past events in order to time the market based on Tempest Therapeutics noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tempest Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tempest Therapeutics' short interest history, or implied volatility extrapolated from Tempest Therapeutics options trading.

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.